Mifomet

Metformin Hydrochloride and Sitagliptin, the active ingredients in Mifomet, are a biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adults by improving insulin sensitivity and enhancing glucose‑dependent insulin secretion, targeting both hepatic glucose production and incretin pathways for complementary glycaemic control.

GNH USA supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifomet is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring pharmacologic glycaemic control.

- Type 2 diabetes mellitus: improves overall blood glucose control when diet, exercise, and monotherapy are insufficient. - Adjunct therapy: used together with other antidiabetic agents such as insulin or sulfonylureas to achieve target HbA1c levels. - Metabolic syndrome with hyperglycaemia: assists in reducing fasting and post‑prandial glucose concentrations.

Mifomet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with insulin or sulfonylureas. - Metallic taste: transient oral sensation.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: marked low blood glucose requiring medical intervention. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Allergic reactions: rash, pruritus, or angio‑edema. - Hepatic or renal dysfunction: worsening of pre‑existing organ impairment.

When prescribing Mifomet, clinicians should consider several safety factors to minimise risk.

- Renal function: assess creatinine clearance; avoid in severe renal impairment. - Hepatic disease: use with caution in patients with liver dysfunction. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Concomitant insulin or sulfonylureas: monitor blood glucose closely to prevent hypoglycaemia. - Alcohol consumption: advise patients to limit intake as it may increase lactic acidosis risk. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Mifomet can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing risk of metformin‑associated lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin plasma levels, heightening hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: enhanced glucose‑lowering effect may cause hypoglycaemia. - Cimetidine: may modestly increase sitagliptin concentrations. - Diuretics (thiazides): can affect renal clearance of metformin, requiring dose adjustment.